A5102947467- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Cancer Cells and Metastasis
- Colorectal Cancer Surgical Treatments
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Biochemical and Molecular Research
- Cancer Diagnosis and Treatment
- Biomedical Text Mining and Ontologies
- Colorectal Cancer Screening and Detection
- Metastasis and carcinoma case studies
- Colorectal and Anal Carcinomas
- Clinical practice guidelines implementation
- HER2/EGFR in Cancer Research
- Inflammatory mediators and NSAID effects
- Digestive system and related health
- Ocular Oncology and Treatments
- Viral-associated cancers and disorders
- PI3K/AKT/mTOR signaling in cancer
- Urinary Bladder and Prostate Research
- Hepatocellular Carcinoma Treatment and Prognosis
Chiba Cancer Center
2021-2023
Tokyo University of Science
2023
National Hospital Organization
2012-2023
National Disaster Medical Center
2023
National Cancer Center
2023
National Cancer Centre Japan
1997-2021
National Cancer Center Hospital East
2001-2019
Tokyo National Hospital
2015
Shizuoka Cancer Center
2012
Sakai Municipal Hospital
2012
Colorectal cancer is a major cause of death in Japan, where it accounts for the largest number deaths from malignant neoplasms among women and third men. Many new methods treatment have been developed during recent decades. The Japanese Society Cancer Colon Rectum Guidelines 2014 colorectal (JSCCR 2014) prepared as standard strategies cancer, to eliminate disparities institutions, unnecessary insufficient treatment, deepen mutual understanding health-care professionals patients by making...
For patients with RAS wild-type metastatic colorectal cancer, adding anti-epidermal growth factor receptor (anti-EGFR) or anti-vascular endothelial (anti-VEGF) monoclonal antibodies to first-line doublet chemotherapy is routine, but the optimal targeted therapy has not been defined.To evaluate effect of panitumumab (an anti-EGFR antibody) vs bevacizumab anti-VEGF standard for treatment wild-type, left-sided, cancer.Randomized, open-label, phase 3 clinical trial at 197 sites in Japan May...
LBA1 Background: PARADIGM is the first prospective trial to test superiority of PAN vs. BEV in combination with standard doublet first-line chemotherapy for patients (pts) RAS WT mCRC and left-sided primary tumors. Methods: This open-label, multicenter Japan (NCT02394795) randomly selected pts chemotherapy-naive + mFOLFOX6 or mFOLFOX6. Overall survival (OS) as endpoint was hierarchically tested tumors, followed by those full-analysis set (FAS) population. Key secondary endpoints included...
The latest World Health Organization (WHO) classification divides adenocarcinoma mainly into mixed subtypes, acinar adenocarcinoma, papillary bronchioloalveolar carcinoma, and solid with mucin production, it mentions several variants, including fetal mucinous (“colloid”) cystadenocarcinoma, signet-ring clear cell adenocarcinoma. In general, the mucin-producing of lung comprises carcinoma (SRCC), production (SA), (m-BAC), adenocarcinomas and/or mucoepidermoid carcinoma. As SRCC, SA, m-BAC...
<h3>BACKGROUND</h3> There is a difference in the location of colorectal mucosal lesions and invasive cancers. <h3>AIMS</h3> To ascertain whether neoplasms reflects carcinogenesis pathway. <h3>METHODS</h3> The subject material consisted 4147 neoplastic that had been resected endoscopically or surgically from 5025 patients. Mucosal submucosal cancers were classified into depressed non-depressed types histologically. relations between macroscopic type, size, histology, investigated....
We aimed to compare the sensitive and quality-controlled KRAS testing with direct sequencing assess impact on decision making of treatment. analysed genomic DNA isolated from macrodissected formalin-fixed paraffin-embedded specimens by an amplification refractory mutation system–Scorpion assay (ARMS/S) method. Cetuximab was administered patients identified as having wild-type (WT) using sequencing. Therapeutic effects were evaluated according their status determined ARMS/S. Among 159...
Abstract Background Although ductal resection margin status in extrahepatic cholangiocarcinoma is evaluated by intraoperative histological examination of frozen sections, its clinical relevance remains controversial. Methods Material taken from patients who underwent R0 or R1 for with the final margins between 1994 and 2003 were reviewed. The following classification was used: insufficient, negative malignancy (NM), undetermined lesion (UDL) positive (PM). Multivariable analyses overall...
Three cases of esophagectomy for secondary esophageal carcinoma metastasized from the ovary, breast and lung are reported. Long-term survival, 14 4 years, after was achieved in two patients. The intervals between surgery primary cancer dysphagia onset these patients were 16 7 respectively. An aggressive surgical approach appears to be therapeutic procedure choice metastatic when tumor growth rate is suspected slow. Autopsy data on 1835 revealed 112 (6.1%) had metastasis esophagus. most...
KRAS mutations are predictive markers for the efficacy of anti-EGFR antibody therapies in patients with metastatic colorectal cancer. Although mutational status is reportedly highly concordant between primary and lesions, it not yet clear whether genotoxic chemotherapies might induce additional mutations. A total 63 lesions (23 baseline primary, 18 24 post-treatment metastatic) from 21 who were treated FOLFOX as adjuvant therapy stage III/IV cancer following curative resection examined. The...
The relationships between gene expression, protein and enzymatic activity of thymidylate synthase (TS) dihydropyrimidine dehydrogenase (DPD) have not been clarified in tumor non-tumor tissues human. In this study, we compared three different parameters by evaluating TS DPD levels, mRNA expression assessed RT-PCR, evaluated immunohistochemical examination, measured biochemical assay, the tissue adjacent normal mucosa 43 patients with gastrointestinal cancer. was significantly higher than both...
ObjectiveThe concordance of KRAS mutation detection between the amplification refractory system–Scorpion assay and direct sequencing was evaluated with clinically available formalin-fixed, paraffin-embedded specimens metastatic colorectal cancers.
Abstract Accurate terminology is the basis for clear communication among specialists and relies upon precise definitions, indispensable WHO Classification of Tumours. We identified a number potentially misleading terms in use recently published Tumours, 5 th edition. From list common sources that might be consulted by pathology field, we searched definitions terms. Where at least two provided term, assessed their level agreement using an ad hoc developed scale. 26 from edition Digestive...
Transgelin is an actin-binding protein expressed in smooth muscle cells, cancer cells and fibroblasts. While has previously been reported to be a tumor suppressor, recent studies have shown that involved carcinogenesis, with its mRNA expression associated poor prognosis colorectal cancer. To date, however, very few clinicopathological conducted on tissue. The aim of this study was therefore elucidate the role stromal cells. Ninety-six patients undergoing curative surgery for between February...
ObjectiveIncreased serum human epidermal growth factor receptor 2 levels have been found in metastatic breast cancer patients and are correlated with overexpression tumor cells. However, the prevalence of gastric has not elucidated.
BackgroundIt remains unclear whether an anti-VEGF or anti-EGFR antibody with standard doublet chemotherapy is the optimal first-line treatment in patients RAS (KRAS/NRAS) wild-type metastatic colorectal cancer (mCRC). Here we outline PARADIGM study (NCT02394795), designed to evaluate superiority of panitumumab over bevacizumab, combination oxaliplatin/5-fluorouracil/leucovorin (mFOLFOX6) chemotherapy-naïve mCRC.Patients and MethodsEligible are aged 20 79 years ECOG performance status 0-1...
3508 Background: The PARADIGM trial (NCT02394795) showed longer median overall survival (OS) with first-line mFOLFOX6 plus panitumumab (PAN) vs bevacizumab (BEV) in patients (pts) RAS wild type (WT) and left-sided metastatic colorectal cancer (mCRC; 37.9 34.3 months, respectively; hazard ratio [HR], 0.82; P=0.031) similar OS right-sided pts (HR 1.09; Yoshino T, et al. ASCO 2022 LBA1). Based on current guideline recommendations regarding clinically relevant biomarkers, here we report clinical...
About 50% of colorectal adenocarcinoma in humans have been reported to contain mutated Ki-ras gene. To provide a better understanding for the possible role this mutation and examine whether its presence can reliably predict risk cancer, we analyzed normal appearing mucosa patients with adenocarcinoma. With an Enriched PCR procedure, detect allele 10(3) 10(4) alleles. Only by procedure was detected non-neoplastic colonic 9 out 50 (18%) Japanese cancer. This analysis indicated that epithelial...
85 Background: The optimal choice of monoclonal antibodies (mAbs) for first-line treatment in patients (pts) with RAS ( KRAS/NRAS) wild-type metastatic colorectal cancer (mCRC) remains controversial. meta-analyses subgroup analyses phase III studies pts KRAS exon 2 mCRC suggested a longer overall survival (OS) an anti-EGFR mAb over bevacizumab or left-sided primary tumors. However, there has been no prospective study comparing the two mAbs these pt populations. This randomized was originally...
TPS776 Background: Optimal combination of monoclonal antibody (anti-VEGF vs. anti-EGFR antibody) with standard chemotherapy as first-line treatment in patients (pts) RAS (KRAS/NRAS) wild-type metastatic colorectal cancer (mCRC) remains controversial. FIRE-3 study demonstrated a significant improvement overall survival (OS) over bevacizumab pts KRAS exon 2 wild type mCRC, while CALGB 80405 did not. PARADIGM is designed to compare panitumumab combined mFOLFOX6 chemotherapy-naive mCRC. Methods:...
53 Background: Excision repair cross-complementing group 1 (ERCC1) is thought to be involved in resistance platinum-based therapy. Recently, expression of this gene was shown associated with the outcome patients gastric cancer. Biomarker analysis conducted evaluate influence on outcomes enrolled ACTS-GC study, a randomized phase III trial, which demonstrated efficacy adjuvant treatment S-1 after D2 dissection for stage II and cancer (Sakuramoto et al., NEJM 2007). Methods: Formalin-fixed...